EMBECTA CORP (EMBC)
Health Care · Diabetes care medical devices · NASDAQ
A standalone diabetes care device manufacturer specializing in blood glucose monitoring and insulin delivery solutions.
What EMBECTA CORP does
Embecta Corp manufactures and sells diabetes care devices, including blood glucose monitoring systems and injection devices. The company develops and markets medical devices that support diabetes management and monitoring for patients and healthcare providers.
Themes: ["Diabetes care","Medical devices","Point-of-care diagnostics"]
Fundamentals
- Price$3.18 as of 2026-07-09 close
- Market cap$189M as of 2026-07-10
- 1-year return-70.0% as of 2026-07-09 close
- P/E1.69 as of 2026-07-10
- Net margin+10.7% as of 2026-07-10
- Gross margin+61.9% as of 2026-07-10
- ROE+6.1% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)-3.4% as of 2026-07-10
- Revenue CAGR (3y)-1.5% SEC XBRL
- Beta0.85 as of 2026-07-10
Dividend: yield +14.4%; 4-year non-decreasing per-share dividend streak (SEC XBRL).
Key risks (from latest filing)
["Declining revenue (-3.43% YoY) despite profitability suggests market pressure or share loss in competitive diabetes device market","Negative equity position of -$626.1M as of March 2026 with substantial accumulated deficit of -$424.7M, indicating long-term financial stress from historical losses","High debt burden with $1.3B in long-term debt relative to market cap of $188.7M, creating refinancing and solvency risk"]
Competitors & peers
- Abbott Laboratories (ABT)
- Medtronic (MDT)
- Novo Nordisk (NVO)
- Roche Diagnostics
- Dexcom (DXCM)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.